Roche reported on an increase of 7% in the entire year in 2024 in constant courses (CER), reaching 60.5 billion of CHF (66.9 billion USD). Growth is encouraged by a strong demand for new medicines, which compensates for the decreasing revenue from the older products that face generic competition.
The company’s operational profit increased by 14% to 20.8 billion. The basic earnings per share (EPS) increased by 7% at CER, and Roche said that the continuous high-digit growth of 2025 was targeted, supported by cost savings and strong sales of key remedies like Vabymmo (Pharicimub-SVOA) and the drug) for cancer) phesgo (pertuzumab / trastuzumab / hyaluronidaza-ZZZFX).
Sales in Roche’s pharmaceutical division increased by 8% to 46.2 billion CHF (50.9 billion USD), encouraged by Vabysmo and Phesgo, as well as the drug with sclerosis Ocrevus (Ocrelizumab) and hemophilia treatment hemlibra (Emicizumab-KXWH). In combination, these products withdrawn in CHF 16.9 billion ($ 18.6 billion), marking 3.3 billion CHF ($ 3.6 billion) increased during 2023.
Vabsymo, launched at the beginning of 2022, was an extraordinary performer Roche, generating CHF 3.9 billion ($ 4.3 billion) for sale due to increasing demand. However, Roche faced the fall of CHF 1 billion sales from loss of exclusivity on older products, including therapy Avastin (Bevacizumab), Herceptin (Trastuzumab) and Rituxan (Rituximab). The expected drop of Coidd-19 products also aspired to the overall growth, reducing the CHF 1 billion ($ 1.1 billion).
On January 30, the invitation to make money, Roche’s Executive Director Thomas Schinecker emphasized that the approach of the company will continue to focus on property with strong scientific support and those who make sense. The company remains dedicated to five key therapeutic areas – cardiovascular metabolism, oncology, neurology, immunology and ophthalmology.
The key recent acquisition was Poseidi Therapeutics on offer of $ 1.5 billionwhich was set up to strengthen Roche’s position in autoimmune diseases. The company was initially in partnership with Poseid in oncology, but expanded its investment after seeing promising information in lupus nephritis. Schinecker described such offers as “in a sweet spot” of Roche’s strategic priorities.
Roche also announced the adjustments of his research and development, abolishing two candidates for Buspecific antibodies at an early stage. The company has given up on a bisper-long RG6194 HER2XCD3 (Runtimotamab), which is developed for breast cancer, and immunotherapy Efbalropendek alpha based on the IL-15, which is designed to stimulate T cells and natural killers. Il-15 property was initially acquired by Xencor As part of a $ 120 million contract, which later revised its partnership conditions, giving up the cost division in favor of paying based on a turning point.
